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Abstract: Leukocyte adhesion contributes to perfusion abnormalities and tissue damage 
during trauma, shock or overwhelming inﬂ  ammation. This study was performed to determine 
whether the lipoxygenase inhibitor phenidone and derivatives decrease the expression of adhe-
sion molecules on tumor necrosis factor-α (TNF-α) stimulated endothelial cells and attenuate 
leukocyte-endothelial interactions under ﬂ  ow in vitro. TNF-α stimulated human umbilical 
venous endothelial cells (HUVECs) were incubated with phenidone, 4-methyl-phenidone, 
4-4-dimethyl-phenidone, 5-methyl-phenidone, 5-phenyl-phenidone, and 5-methyl-1,(2,5-di-
chloro-phenyl)-3-pyrazolidone. We tested the inhibition of adhesion molecule expression at 
different inhibitor concentrations before, during, and after the stimulation of HUVECs. The 
inhibition of endothelial cell expression on HUVECs was measured by ﬂ  ow cytometry. Roll-
ing and ﬁ  rm adhesion of leukocytes to pretreated endothelium was examined in a parallel plate 
ﬂ  ow chamber. Phenidone inhibited the expression of intercellular adhesion molecule-1, vascular 
cell adhesion molecule-1, and endothelial-leukocyte adhesion molecule-1 on HUVECs when 
added prior to HUVEC stimulation. The inhibitory effect of phenidone was still observed when 
added simultaneously, but not when added after HUVEC stimulation. 4-4-dimethyl-phenidone 
and 5-phenyl-phenidone inhibited the expression of adhesion molecules more effectively than 
phenidone. The attenuation of leukocyte rolling under ﬂ  ow conditions was also signiﬁ  cantly 
more effective with 4-4-dimethyl-phenidone than with phenidone. Lipoxygenase inhibitors 
might be of therapeutically interest for the treatment of overwhelming systemic inﬂ  ammation 
during shock, trauma, and sepsis.
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Introduction
The inﬁ  ltration of infected tissue by leukocytes is important for the innate immune 
response. Before leaving the vascular system, the leukocytes must make contact with 
the endothelial cells of the vessel wall. Once this contact has been established, the 
leukocytes transmigrate through the tissue and ﬁ  ght local inﬂ  ammatory processes by 
various defense mechanisms.
Systemic inﬂ  ammatory response syndrome (SIRS) is a systemic event and is deﬁ  ned 
by clinical parameters such as body temperature, heart rate, respiratory insufﬁ  ciency, 
and leukocyte count in the context of a typical clinical setting with or without a con-
ﬁ  rmed infection (Bone 1992). Leukocyte adhesion is a hallmark of shock, overwhelm-
ing inﬂ  ammation and ischemia/reperfusion injury (Vedder et al 1988; Eppihimer and 
Granger 1997; Singbartl et al 2000). In the case of systemic inﬂ  ammation, there is Biologics: Targets & Therapy 2008:2(1) 152
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widespread transmigration of leukocytes from the vascular 
system through the activated tissue. The high mortality rate 
associated with this syndrome is due in part to the fact that the 
inﬂ  ammatory process is not kept at a local level, but spreads 
throughout the body. Leukocyte diapedesis has detrimental 
effects on innate immunity and causes the failure of organs 
such as kidneys, liver, lungs, etc.
On endothelial cells, the expression of endothelial-
leukocyte adhesion molecule-1 (E-selectin), ICAM-1 
(intercellular adhesion molecule-1), and VCAM-1 (vascular 
cell adhesion molecule-1) leads to a multistep process of 
leukocyte-endothelial interaction. Following transient rolling 
interactions mediated by selectins, the binding of ICAM-1 
and VCAM-1 to their integrin counterreceptors results in ﬁ  rm 
adhesion of the leukocytes, which ﬁ  nally transmigrate into 
the subendothelial tissue (Jaeschke and Smith 1997; Ramos 
et al 1997). Concomitant signaling via adhesion molecules 
activates the interacting cells (Hlasta et al 1991). Since 
leukocyte-endothelial interactions are a crucial contribu-
tor to many aspects of organ dysfunction in critical illness 
(Singbartl et al 2000), the reduction of adhesion molecule 
expression on activated endothelial cells could be a therapeu-
tic option to attenuate leukocyte-mediated tissue injury.
5-lipoxygenase pathways are widely distributed within 
mammalian cells and catalyze the production of leukotrienes, 
which act as potent biological mediators (Cuzzocrea et al 
2004; Zhao et al 2004). Leukotrienes can be synthetized by 
vascular endothelial cells, smooth muscle cells, neutrophils, 
macrophages, platelets, etc., and themselves can trigger the 
expression of adhesion molecules on the surface of endothe-
lial cells and leukocytes (Reilly et al 2004). The principal 
substrate for leukotrienes is arachidonic acid. In a next step, 
the enzymes cyclooxygenase and lipoxygenase catalyze the 
production of prostaglandins and leukotrienes, respectively. 
The lipoxygenases are classiﬁ  ed according to the position 
at which they oxidize arachidonic acid. Leukotriene B4 
(LTB4) is a potent activator of human leukocytes and can 
induce inﬂ  ammatory reactions such as polymorphonuclear 
activation, migration and adhesion by nuclear factor-kappa 
B (NF-κB) activation. The biological potency of leukotrienes 
has stimulated the search for 5-lipoxygenase inhibitors with 
antiinﬂ  ammatory potency in a multitude of medical ﬁ  elds 
(De Caterina and Zampolli 2004; Gaddi et al 2004; Wang 
et al 2004).
1-phenyl-3-pyrazolidinone (phenidone) is a combined 
5-lipoxygenase and cyclooxygenase inhibitor. Increased 
lipophilicity of phenidone derivatives is correlated with 
increased inhibitor potency. By preventing the oxidation 
of arachidonic acid to 5-HPETE we may be able to inhibit 
5-lipoxygenase.
In this study, we tested the ability of phenidone and potent 
derivatives to inhibit the expression of adhesion molecules 
E-selectin, ICAM-1, and VCAM-1 on activated human vas-
cular endothelial cells (HUVECs). We also measured their 
potential to inhibit leukocyte rolling and ﬁ  rm adhesion in a 
dynamic ﬂ  ow assay.
Materials and methods
Antibodies and reagents
Fluorochrome-conjugated murine monoclonal antibodies 
(mAb) against CD11b (IgG1, ﬂ  uorescein conjugates, Caltag, 
San Francisco, CA), CD15 (IgM, phycoerythrin-conjugate), 
CD45, CD62L (IgG1, fluorescein-conjugates, Becton 
Dickinson, San Jose, CA), Lewis X, E-selectin, VCAM-1 
(CD15, CD62E and CD106; IgM and IgG1, ﬂ  uorescein-
conjugates, Southern Biotechnologies, Birmingham, AL), 
and ICAM-1 (CD54; IgG1, phycoerythrin-conjugate, 
Immunotech, Marseille, France) were used in saturating 
amounts for subsequent ﬂ  ow cytometric analysis of cell 
surface antigen expression (FACSortTM, Becton Dickinson, 
San Jose, CA). Isotype-matched control antibodies were 
purchased from the manufacturers of the corresponding 
speciﬁ  c antibodies.
Phenidone and derivatives were obtained from Hampford 
Research Inc., Stratford, Connecticut, USA (Figure 1). 
Derivatives were dissolved with DMSO to a ﬁ  nal concentra-
tion of 0.2% in cell culture medium. In control experiments, 
no inﬂ  uence of DMSO on the adhesion molecule expression 
of activated HUVECs was observed.
Cell culture and human 
polymorphonuclear neutrophil isolation
Human umbilical venous endothelial cells (HUVECs) were 
harvested from freshly prepared umbilical cords by enzy-
matic treatment of the umbilical vein with collagenase A 
0.1% (Wakatsuki et al 1999). The cells were grown at 37 °C 
and 5% CO2 in endothelial cell growth medium containing 
fetal calf serum 2%, epidermal growth factor 0.1 ng/ml, basic 
ﬁ  broblast growth factor 1.0 ng/ml, gentamicin 50 μg/ml, 
amphotericin B 0.05 μg/ml and 20 μl endothelial cell growth 
supplement/heparin. This preparation yielded a purity and 
viability of 90% as conﬁ  rmed by staining for von Wil-
lebrand factor and trypan blue exclusion. After the ﬁ  rst 
passage, the cells were plated at high density on either col-
lagen-treated 12-well plates or rectangular coverslips (No. 
1.5 thickness, Kindler, Freiburg, Germany) precoated with Biologics: Targets & Therapy 2008:2(1) 153
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collagen I and used for the experiment 48 h later after they 
had reached conﬂ  uency.
Human polymorphonuclear neutrophils (PMN) were 
isolated from citrated blood by density gradient centrifuga-
tion at 1700 rpm on a discontinuous Percoll gradient with 
63% and 72% Percoll in phosphate buffer solution (PBS) 
(Percoll, 1.130 g/ml; Amersham Pharmacia Biotech, Uppsala, 
Sweden). The bottom layer, containing the polymorpho-
nuclear neutrophil granulocytes (PMN), was collected; 
contaminating erythrocytes were removed by hypotonic 
lysis in 10% NH4Cl on ice. Following a ﬁ  nal wash with cold 
PBS, the PMN pellet was resuspended in cold medium 199 
at 5 × 107/ml. As determined by light scatter and cell sur-
face antigen analysis of CD15, CD45, CD62L, and CD11b, 
separation yielded functionally intact, non-activated PMNs 
at 90% purity, with only minimal alterations in surface 
molecules that are sensitive markers for activation. Samples 
were obtained after obtaining written consent and approval 
of the local ethics committee.
Endothelial cell activation
To determine the inhibitory effect of lipoxygenase-cyclo-
oxygenase inhibitors on adhesion molecule expression on 
endothelial cells, HUVECs were stimulated with tumor 
necrosis factor-α (TNF-α) (0.5 ng/mL) (Sigma, St. Louis, 
MO, USA) 2 h before (preincubation), simultaneously with 
(coincubation), or 2 h after (postincubation) the addition of 
the lipoxygenase-cyclooxygenase inhibitor (Figure 2). The 
inhibitor was added in increasing concentrations up to 2 mMol 
for 4 h (pre- and postincubation) or 6 h (coincubation). The 
ﬁ  nal concentrations of lipoxygenase-cyclooxygenase inhibi-
tors employed in ﬂ  ow assays were determined in preliminary 
Figure 1 Phenidone derivatives.
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experiments examining the effects of different concentrations 
of inhibitors on adhesion molecule expression and cell 
viability. Control experiments consisted of the incubation of 
HUVECs with medium alone, or the activation of adhesion 
molecule expression without the addition of an inhibitor. At 
the end of a 6 h incubation period, the response to stimulation 
was determined by ﬂ  ow cytometric analysis of endothelial 
cell adhesion molecules. Prior to the measurement, HUVECs 
were labelled with 20 μl of mAb against E-selectin, ICAM-1, 
and VCAM-1 for 30 min at room temperature, washed, and 
trypsinized.
Endothelial-PMN interactions 
in the ﬂ  ow chamber
Cell adhesion was examined morphometrically from 
digitized video recordings of perfusion experiments using 
computer-based image recognition. Corresponding to the 
above experiments, HUVEC monolayers were grown on 
coverslips and treated according to the pre-incubation setup 
described above. After washing, the coverslips were placed 
within a heatable metal case located on the stage of an 
inverted microscope (DMIRB, Leica, Bensheim, Germany). 
The ﬂ  ow rate Q in ml/sec necessary to produce the desired 
shear stress τw could be calculated according to the formula 
Q = (h2wτw)/6 μ, in which h is the chamber height, w is the 
width and μ is the viscosity of the perfusate (0.007 poise for 
isolated neutrophils). We performed the experiments at a 
shear stress of 2 dynes/cm2. PMN suspension (106 cells/mL) 
was perfused through the ﬂ  ow chamber via a syringe pump. 
Total PMN adhesion, including rolling and ﬁ  rm interactions 
with the endothelial monolayer, was determined from ﬁ  ve 
randomly chosen ﬁ  elds of view (200 × magniﬁ  cation) at the 
end of each 10 min perfusion period. PMN were considered 
to be adherent (sticking) when a cell was moving less than 
one cell diameter within 10 sec (Figure 5). The number of 
rolling interactions between PMN and the endothelial cell 
monolayer were calculated from 60 video sequences derived 
from a single ﬁ  eld of view over a period of 3–4 min dur-
ing each experimental run. Rolling velocities (μm/s) were 
calculated as previously described (Nohé et al 2002, 2003). 
PMN with rolling velocities of 0.7 μm/s were counted as 
rollers. Data are expressed as percent sticking or rolling cells 
compared with controls.
Statistical analysis
Cell surface antigen expression was measured on the basis 
of mean ﬂ  uorescence intensities calculated from 5000 single 
events detected by the ﬂ  ow cytometer for each sample. The 
effects of the lipooxygenase inhibitors in the ﬂ  ow cytom-
eter analysis are expressed as percent expression of TNF-
α  activation alone minus the unstimulated expression of 
adhesion molecules on HUVECs. All data were tested for 
normal distribution and transformed where necessary. Effects 
of treatment (pre-, co-, post-inhibition) and effects of the 
derivative concentration on adhesion molecule expression 
were examined using an analysis of variance (ANOVA) 
followed by Bonferroni-Holm adjustment. As indicated 
by an R-square of 0.82, the ANOVA attributed 82% of the 
variation to the model. The inhibitor concentration that lead 
to a 50% inhibition of adhesion molecule expression (IC50) 
was calculated, assuming a logarithmic dose-response 
relationship. Unless otherwise stated, data are presented as 
means ± standard deviation. Statistical signiﬁ  cance was set 
at p  0.05. Statistical computation was carried out using 
JMP software (SAS Institute, Cary, NC, USA).
Results
Effects of the timing and concentration 
of phenidone administration on
the adhesion molecule expression 
of activated HUVECs
The expression of ICAM-1, VCAM-1, and E-selectin 
on HUVECs was stimulated by TNF-α (0.5 ng/mL). We 
measured the inhibitory effect of phenidone on adhesion 
Figure 2 Experimental setup.
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molecule expression when added either two hours before 
(pre-incubation), at the same time as (co-incubation), or two 
hours after (post-incubation) the stimulation of HUVECs by 
TNF-α. The experimental setup is shown in Figure 2. Three 
different phenidone concentrations were tested: 0.5, 1.0, and 
2.0 mM. The results are shown in Figures 3A–C. Phenidone 
signiﬁ  cantly decreased the expression of adhesion molecules 
on the surface of HUVECs when administered two hours 
before the stimulation of HUVECs by TNF-α (p  0.01, 
(n = 4). The inhibition of adhesion molecule expression 
Figure 3 Inhibition of adhesion molecule expression by phenidone.
The decrease of adhesion molecule expression (ICAM-1, VCAM-1, E-selectin) is plotted in a logarithmic dose-response relationship (curve ﬁ  tting). X-axis: Concentration of 
phenidone (μM). Y-axis: Per cent inhibition of adhesion molecule expression in relation to maximal TNF-α induced expression. Fine-dotted lines: Pre-incubation – phenidone 
was added 2 hours before TNF-α stimulation. Coarse-dotted line: Co-incubation – simultaneous application of phenidone and TNF-α. Solid line: Post-incubation – phenidone 
was added 2 hours after TNF-α stimulation.
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was still significant when phenidone and TNF-α were 
co-administered (co-incubation). In contrast, when phenidone 
was given two hours after the stimulation of HUVECs by TNF-
α no decrease in adhesion molecule expression was observed. 
Furthermore, the inhibition of adhesion molecule expression 
was concentration-dependent (p  0.01). The highest phe-
nidone concentration (2.0 mM) led to the greatest inhibition 
of adhesion molecule expression on HUVECs. There was no 
statistical difference between the individual inhibitions of the 
three adhesion molecules tested (p = 0.14).
Static effects of phenidone derivatives 
on the adhesion molecule expression 
of activated HUVECs
The ability of the phenidone derivatives 4-methyl-phenidone, 
5-methyl-phenidone, 4-4-dimethyl-phenidone, 5-phenyl-
phenidone, and 5-methyl-1,(2,5-di-chloro-phenyl)-3-pyr-
azolidone to inhibit the adhesion molecule expression on 
HUVECs was tested when they were administered before 
the activation of HUVECs (pre-incubation). HUVECs were 
incubated with increasing concentrations of the derivatives 
between 125 and 2000 μM. All experiments were repeated 
at least three times. To quantify the ability of the derivatives 
to inhibit adhesion molecule expression, we calculated the 
inhibitor concentration that lead to a 50% inhibition of adhe-
sion molecule expression (IC50), assuming a logarithmic 
dose-response relationship. The results are shown in Figure 4. 
The expression of ICAM-1 was signiﬁ  cantly reduced after 
pre-incubation of HUVECs with 4-4-dimethyl-phenidone and 
5-phenyl-phenidone (IC50 382 ± 67 μM and 202 ± 102 μM, 
respectively) (p  0.01) compared with the inhibition of 
adhesion molecule expression by phenidone (IC50 1128 ± 
371 μM). Similarly, the expression of E-selectin was signiﬁ  -
cantly reduced with these two compounds (IC50 216 ± 138 
μM and 169 ± 41 μM) compared to phenidone (IC50 861 
± 338 μM). In contrast, 4-methyl-phenidone and 5-methyl-
phenidone did not reduce adhesion molecule expression 
more effectively than phenidone (4-methyl-phenidone: 
IC50 of 1542 ± 1062 μM for ICAM-1 and 619 ± 183 μM 
for E.-selectin; 5-methyl-phenidone: IC50 1615 ± 819 for 
ICAM-1 and 1461 ± 774 μM for E-selectin). No inhibition 
of the adhesion molecule expression was observed with 
5-methyl-1,(2,5-di-chloro-phenyl)-3-pyrazolidone (not 
shown). Also, compared with phenidone, the expression of 
Figure 4 Inhibition of ICAM-1, VCAM-1, and E-selectin by phenidone and derivatives.
IC50: The inhibitor concentration yielding 50% inhibition of adhesion molecule expression. *=signiﬁ  cant reduction of ICAM-1, and E-selectin expression after preincubation 
with the denoted derivative, compared to phenidone (p < 0.01).
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VCAM-1 was not signiﬁ  cantly reduced after pre-incubation 
with any of the tested derivatives.
Dynamic adhesion of polymorphonuclear 
granulocytes to HUVECs
Under venular shear forces (2 dynes/cm2) PMN adhesion to 
untreated endothelial cells was negligible after 10 min of perfu-
sion (not shown). On cytokine-activated HUVECs, total PMN 
adhesion increased 10-fold (Figures 5A–B). In subsequent 
experiments, the effect of 4-4-dimethyl-phenidone, which 
signiﬁ  cantly reduced adhesion molecule expression in the 
static experiments, was compared to phenidone. Pretreatment 
of endothelial cells with 4-4-dimethyl-phenidone or phenidone 
(both 400 μM) prior to cytokine-activation significantly 
reduced total PMN adhesion (p  0.01; Figures 5C–D) com-
pared with untreated activated HUVECs. When rolling and 
ﬁ  rm adhesion were examined separately, it became obvious 
that 4-4-dimethyl-phenidone had a signiﬁ  cantly stronger inhib-
itory effect on rolling interactions than phenidone (p  0.05). 
However, the number of adherent PMN was not signiﬁ  cantly 
reduced after preincubation of HUVECs with 4-4-dimethyl-
phenidone rather than phenidone (Figure 6).
Discussion
The cytokine-triggered expression of adhesion molecules 
on the surface of vascular endothelial cells is observed in 
Figure 5 Endothelial-PMN interactions in the ﬂ  ow chamber.
Endothelial cell surface layer after activation with TNF-α for 4 hours. The experiments were performed at a shear stress of 2 dyn/cm2 with PMN (106 cells/mL). A: PMN were 
considered to be adherent (sticking) when a cell moved less than one cell diameter within 10 sec. Four adherent PMNs (ﬂ  ashes) were counted from digitized video recording. 
B: The same endothelial cell surface as shown in A. PMNs with rolling velocities of 0,7 μm/s were counted as rollers. In A and B four rolling PMNs were marked by circles. 
C: Endothelial cell surface layer after pre-incubation with 4-4- dimethyl-phenidone (400 μM). No adherent PMNs were counted from this sequence. D: The same endothelial 
cell surface as shown in C. Only 1 rolling PMN is counted.
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states of severe sepsis, ischemia reperfusion injury, or SIRS. 
The inhibition of adhesion molecule expression on activated 
vascular endothelial cells could be of therapeutic interest for 
the attenuation of leukocyte-mediated tissue injury (Singbartl 
and Ley 2000; Peters et al 2003). Using cell-surface antigen 
analysis and a dynamic adhesion assay, we were able to 
demonstrate that treatment of cytokine-activated HUVECs 
with the lipoxygenase inhibitor 1-phenyl-3-pyrazolidinone 
(phenidone) reduced both adhesion molecule expression and 
subsequent adhesion of PMN to vascular endothelial cells 
under postcapillary shear stress. Compared to phenidone, 
treatment of HUVECs with the derivatives 4-4-dimethyl-
phenidone and 5-phenyl-phenidone was signiﬁ  cantly more 
effective.
The inhibition of adhesion molecule expression was 
dependent on the time and concentration of the inhibitor. 
In addition, while treatment before or at the same time as 
cytokine-triggered activation of adhesion molecule expres-
sion led to a reduced adhesion molecule expression, no 
beneﬁ  cial effect could be observed when phenidone was 
administered two hours after TNF-α treatment of HUVECs. 
Similarly, an effect of phenidone could be demonstrated 
on leukocyte adhesion in animal models. Leukocyte adhe-
sion was decreased and capillary permeability increased 
during ischemia-reperfusion injury after pretreatment with 
phenidone in a hamster cheek pouch model and an ischemic 
rat brain damage model (Bertuglia et al 1993; Wakatsuki et al 
1999). The results of these studies indicate that phenidone 
affects adhesion molecule expression in vivo. However, it is 
not clear from these functional studies whether phenidone 
affects adhesion primarily by inhibition of endothelial adhe-
sion molecules or more proximal steps in the inﬂ  ammation 
cascade. We observed a signiﬁ  cant inhibitory effect of 
phenidone on the expression of the endothelial-cell-speciﬁ  c 
adhesion molecules ICAM-1, VCAM-1, and E-selectin only 
when it was administered two hours before or simultaneously 
with TNF-α.
In subsequent experiments, we tested ﬁ  ve derivatives 
to determine whether they might have a stronger inhibitory 
effect on adhesion molecule expression than phenidone. 
In a previously published study, a series of 1-phenyl-3-
pyrazolidinones were tested with respect to their ability 
to inhibit lipoxygenase. In this study, the lipoxygenase 
inhibitory potency was correlated with the lipophilicity of the 
compounds. Furthermore, the introduction of a substituent 
at position four of the pyrazolidinone improved the potency. 
In our study, we used those derivatives found in a previous 
study (Hlasta et al 1991) to inhibit 5-lipoxygenase most effec-
tively, and tested them for their ability to inhibit adhesion 
molecule expression on activated HUVECs. The derivatives 
Figure 6 Rolling and adhesion of PMN to TNF-α stimulated HUVECs after pre-incubation with phenidone or 4-4-dimethyl-phenidone.
The ability of phenidone and 4-4-dimethyl-phenidone to inhibit rolling and adhesion of PMNs is shown as per cent of rolling and adhesion to untreated HUVECs. *=signiﬁ  cant 
reduction of rolling when the HUVECs were pre-incubated with 4-4-dimethyl-phenidone instead of phenidone (p  0.01).
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4-4-dimethyl-phenidone and 5-phenyl-phenidone decreased 
the adhesion molecule expression of ICAM-1 and E-selectin 
signiﬁ  cantly better than phenidone. We observed that the 
inhibitory potential of the derivatives on adhesion molecule 
expression increased as more and more lipohilic side groups 
were introduced in the molecule.
Pyrazolidinones are combined lipoxygenase and cyclo-
oxygenase inhibitors (Hlasta et al 1991). Several mecha-
nisms of action are conceivable behind adhesion molecule 
inhibition by pyrazolidinones. These include lipoxygenase 
inhibition, cyclooxygenase inhibition, antioxydative effects, 
or a combination of the above. A group tested the effect of 
nordihydroguaiaretic acid (NDGA), a potent lipoxygenase 
inhibitor, on the cytokine-triggered inhibition of ICAM-1 and 
VCAM-1 on HUVECs (Lee et al 1997). The authors of that 
study showed that both adhesion molecules were effectively 
inhibited at low concentrations of NDGA (IC50: 50 μM). 
Their results, like ours, demonstrated that an inhibitory 
effect only occurred when the inhibitor was added before 
the cytokine-triggered activation of adhesion molecule 
expression. Subsequent analysis showed that NDGA inhib-
ited the promotor activity of the gene coding for VCAM-1 
by decreasing the functional activity of NF-κB. Several 
studies demonstrated in similar series of experiments that 
adhesion molecule expression is inhibited by lipoxygenase 
inhibitors interacting with the nuclear transcription factor 
AP-1 (Ahmad et al 1994). The activation of transcription 
factors NF-κB and AP-1 by TNF-α triggers the transcrip-
tion and expression of E-selectin, VCAM-1, and ICAM-1 in 
HUVECs. The promotors of the corresponding genes possess 
three, two, and one binding site(s) for NF-κB, respectively 
(Schindler and Baichwal 1994; Ladebur and Parks 1995; 
Sheppard et al 1995). It has been shown that lipoxygenase 
is involved in the signal transduction pathway through the 
RhoA/protein kinase Ca-dependent activation of NF-κB (Los 
et al 1995; Bolick et al 2005). Therefore, compounds with 
improved lipoxygenase inhibition activity could inﬂ  uence the 
adhesion molecule expression on HUVECs by affecting the 
activity of NF-κB and AP-1. However, we did not measure 
a possible correlation between the lipoxygenase activity 
of the derivatives and the inhibitory effect on the adhesion 
molecule expression. For most liopxygenase inhibitors, the 
reported IC50 for lipoxygenase inhibition is less than that 
for adhesion molecule inhibition by a factor of about ten 
(Hlasta et al 1991).
In previous studies, it was shown that the cyclooxygen-
ase inhibitors diclofenac, ibuprofen, and salicylates were 
able to decrease the expression of adhesion molecules on 
vascular endothelial cells (Kapiotis et al 1996; Pierce et al 
1996; Sakai 1996). However, high concentrations were 
necessary to achieve an inhibition of ICAM-1 and VCAM-1. 
The majority of cyclooxygenase inhibitors did not affect E-
selectin expression. Further, the cyclooxygenase inhibitor 
indometacin did not have any effect on adhesion molecule 
expression on vascular endothelial cells. In contrast to lipoxy-
genase inhibitors, which lead to an inhibition of adhesion 
molecule synthesis, cyclooxygenase inhibitors were able 
to downregulate the number of adhesion molecules already 
expressed on the surface of endothelial cells. We did not 
observe a postranslational effect in our experiments with 
combined lipoxygenase and cyclooxygenase inhibitors. Thus, 
cylooxygenase inhibition seems to be of less importance for 
the improved effectiveness of pyrazolidinones.
After treatment with phenidone, VCAM-1 expression 
on HUVECs was more effectively reduced than that of 
ICAM-1 and E-selectin. In addition, 4-4-dimethyl-phenidone 
and 5-phenyl-phenidone reduced the expression of 
ICAM-1 and E-selectin signiﬁ  cantly better than phenidone. 
Both ICAM-1 and E-selectin participate in the transition from 
rolling to ﬁ  rm adhesion (De Caterina and Zampolli 2004; 
Wang et al 2004). Whereas E-selectin decelerates transiently 
rolling leukocytes, ICAM-1 and VCAM-1 contribute to ﬁ  rm 
adhesion by binding to β2-integrins on the neutrophil at slow 
rolling velocities (Steeber et al 1998; Ley 2003). When we 
compared phenidone to 4-4-dimethyl-phenidone with respect 
to their ability to inhibit neutrophil rolling and ﬁ  rm adhesion 
(sticking) in dynamic ﬂ  ow chamber experiments, we found 
that rolling was signiﬁ  cantly better inhibited after incuba-
tion with 4-4-dimethyl-phenidone than with phenidone. This 
result correlated with the signiﬁ  cantly better inhibition of 
E-selectin by 4-4-dimethyl-phenidone than by phenidone.
We observed a higher rate of cell detachment when we 
incubated the HUVECs with inhibitor concentrations of 
2000 μM. However, cell morphology was not altered after 
this treatment. In addition, adhesion molecule expression was 
preserved even at high concentrations of the inhibitors in our 
postincubation experiments. The preservation of functional 
activity as well as the unaltered cell morphology suggests 
that cell toxicity did not occur at these concentrations.
In summary, we found a correlation between reduced adhe-
sion molecule expression on activated HUVECs and subse-
quently impaired adhesion of neutrophils following treatment 
with the phenidone derivatives 4-4-dimethyl-phenidone and 
5-phenyl-phenidone. These lipoxygenase inhibitors might be 
of therapeutical interest in the treatment of overwhelming 
systemic inﬂ  ammation during shock, trauma, and sepsis.Biologics: Targets & Therapy 2008:2(1) 160
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